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Abstract
Background: This study was designed to determine the Human papillomavirus (HPV) prevalence and its
distribution of genotypes in various regions of Yunnan Province, China.
Method: In this study, participants were recruited during routine gynecologic examination between Oct 2013 and
Feb 2015. A total of 17,898 women were recruited. Polymerase chain reaction was used for detecting the HPV
positive samples and HPV geno-array test was used for genotyping.
Results: The overall HPV infection rate (19.9 %) among the south-western women was significantly higher (P = 0.
001) than that among the north-western (18.0 %), south-eastern (13.3 %), north-eastern (11.1 %) and central women
(12.9 %). The high-risk (HR) (18.1 %, P = 0.001) and single genotype (16.7 %, P = 0.001) infection rates among the
South-western women were also significantly higher than those of among the north-western (13.9 %, 11.3 %),
south-eastern (11.6 %, 10.5 %), north-eastern (9.6 %, 9.1 %) and central women (10.5 %, 10.0 %), respectively. While,
the infections with multiple HPV (4.2 %) genotypes were significantly more common (P = 0.001) among women in
north-western Yunnan than women in the south-western (1.3 %, 3.1 %), south-eastern (1.7 %, 2.7 %), north-eastern
(1.5 %, 2.0 %) and central Yunnan (2.4 %, 2.9 %). A total of 30 HPV genotypes were detected; among them 13 were
HR-HPV, 3 were PHR-HPV (Potential High risk), 8 were LR-HPV (Low risk) and six were unclassified. The most
common HPV genotypes were HPV-52, 16, 58, 53 in control group, HPV-16, 52, 58, 39 and 53 in CINI (Cervical
intraepithelial Neoplasia), HPV-52, 16, 58, 33, 53 and 81 in CINII, HPV16, 58, 18, 52, 81 in CINIII and HPV-16 18, 58, 52
in cervical cancer (CC), respectively. Such variation has also been observed about distribution of HPV genotypes
distribution among single and multiple infections.
Conclusion: This study gives an epidemiological estimate of HPV prevalence and different genotype distribution in
various region of Yunnan province and further explains its prevalence in different neoplastic lesions. Overall HPV-16,
52, 58, and 18 are the leading HR-HPV genotypes.
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Background
Human papillomavirus (HPV) infections are the most
frequently sexually transmitted infections throughout
the world. Worldwide, the prevalence of HPV is
approximately 11–12 % [1], and 85 % of the infections
and 88 % of the deaths caused by this virus occur in
developing countries [2]. The prevalence of HPV varies
substantially with respect to ethnicity and geographic
location [3–5].
Papillomaviruses are non-enveloped, circular, double-
stranded DNA viruses with a genome length of 8-kb.
More than 200 HPV genotypes have been reported, almost
40 of which are frequently transmitted through inter-
course and remain in the genital system. Genital HPV in-
fects most sexually active females at some point during
their lives and plays a vital role in the development of cer-
vical cancer [6, 7]. HPV genotypes are classified as high
risk or low risk, according to their carcinogenicity. There
are about one dozen high-risk HPV genotypes, which are
responsible for the formation of malignant lesions [5, 8, 9]
while the low-risk genotypes may promote the develop-
ment of low-grade carcinoma [9, 10]. Epidemiologically,
significant geographic variation in HPV genotype distribu-
tion has been reported. Generally, the HPV-16 genotype is
the most common worldwide, whereas the prevalences of
the other genotypes vary from region to region [9]. Several
HPV genotypes have been reported to cause cervical can-
cer, and geographic variation in the frequencies of these
genotypes has also been reported [11]. Hence, the assess-
ment of the regional distribution of these genotypes is ex-
tremely important for the prevention of cervical cancer.
The prevalence and genotype distributions of HPV are
well documented in developed areas of China. The geno-
types HPV-16, 18, 52, 58 and 59 are most commonly
detected in Chinese women [12–14]. However, the pat-
tern of HPV genotype distribution varies among differ-
ent regions of the country [15]. Further, due an uneven
distribution of cancer registry centres, the actual HPV
prevalence is believed to be higher than the reported es-
timates [4].
Yunnan Province has a unique geographic location,
highly complex topography, and large variations in ele-
vation, and it has a diverse climate because of these dis-
tinctive features [16]. Yunnan is located at the threshold
of the Himalayas. In north-western Yunnan, the moun-
tains are large, the landscape is dry and rugged, and the
weather is cold. It shares a border of 4060 km with
Myanmar in the west, Laos in the south, and Vietnam in
the south-east and the weather is hot in this region. Like
its distinct topographical features, the social characteris-
tics of Yunnan Province are also diverse [17]. Although
individuals in some ethnic groups live in urban areas
with racial admixture, most of them prefer to reside in
individual concentrated communities with distinctive
socio-cultural practices. Yunnan province is the home-
land of a large number of ethnic minorities in China, in-
cluding the Yi, Bai, Hani, Zhuang, Dai, Miao, Lisu, Hui,
Lahu, Va, Naxi, Yao, Tibetan, Jingpo, Blang, Achang, Nu,
Pumi, Jino, Benlong, Mongolian and Drung. Each of
these ethnicities has its own typical customs, architec-
tural style and unique literature. The Han population is
a well-developed ethnic majority in China. It represents
the largest population in this region and is equally dis-
tributed throughout Yunnan. To our knowledge, there
have been no descriptions of the genotype distribution
of HPV in Yunnan province. Therefore, the objective of
the current study was to explore the epidemiological
characteristics of the HPV genotype distributions in vari-
ous regions of Yunnan Province, China and to further
delineate the relationship of HPV genotype distribution
with abnormal and normal cytological findings.
Methods
In this study, participants were recruited during routine
gynecologic examination between Oct 2013 and Feb 2015.
A Women who met the following criteria were recruited:
those who (1) was mentally and physically normal, (2) was
aged between above 18 years, (3) was a permanent resi-
dent of local region; (3) was not a virgin (4) had not
undergone a total hysterectomy; (5) had no history of cer-
vical surgery; (6) had never had pelvic radiation therapy.
Initially 18,562 participants were recruited for this study.
Sixty-three women excluded with due to invalid test result
lesions and 45 were not willing for biopsy while 11 were
excluded due to HPV-genotype lesions. A total of 17,898
women from the central region (n = 7065) north-west re-
gion (n = 3772), north-east region (n = 3152), south-west
region (n = 2164) and south-east region (n = 1745) were
recruited. The study designed and method has been de-
scribed previously [18] with some modification.
Experimental ethics
The protocol used in this study was in accordance with
the Declaration of Helsinki and was approved by the
Ethics Committee at Kunming University of Science and
Technology and the Center for Disease Control and Pre-
vention (CDC) in Yunnan Province, China. Written con-
sent was individually obtained from each participant.
Collection of data and cytological analysis
The women were interviewed at the hospital by trained
interviewers using a standardized questionnaire to elicit
information on socio-demographic risk factors. After the
interview, all women underwent a pelvic examination
performed by a senior gynecologist; two cervical scrapings
were collected for cytological analysis and detection of
HPV DNA. Both conventional smears and liquid-based
cytology were performed.
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All cytological slides were prepared by two qualified
technicians individually. First Cytological slides were
read locally by a junior cytopathologist from each
geographical site according to the Bethesda classifica-
tion system. All Pap smears with a diagnosis of atyp-
ical squamous cells of undetermined significance
(ASC-US) or greater and a 10 % random sample of
normal Pap smears were sent to the Research Center
for Molecular Medicine, Kunming Yunnan for double
cytological review by an expert senior cytopathologist
who was blinded to the original diagnosis. Addition-
ally, the slides read by the junior cytopathologist were
used only for screening. The final diagnosis was the
diagnosis of senior cytopathologist.
Histo-pathological analysis
During colposcopy, the cervix was divided into four
parts and each part was observed individually. All visu-
ally abnormal areas were biopsied. Every part with nor-
mal colposcopic impressions had one random biopsy
collected at the squamo-columnar junction. Endocervi-
cal curettage was then performed. All cervical biopsies
were performed with standard 2 mm POI biopsy forceps,
which allows rapid healing of the biopsy sites and mini-
mizes patient distress. Histological slides were reviewed
by two senior pathologists from Yunnan First Peoples
Hospital.
The cervical intraepithelial neoplasia grading and cer-
vical cancer was diagnosed according to the World Health
Organization classification system (CIN I–III) [19].
HPV genotyping
Samples that tested positive for β-globin were analysed by
PCR amplification of HPV DNA. HPV-positive samples
were confirmed by PCR with universal L1 primer MY09/
11 and GP5/6 systems [20]. DNA from HeLa and Caski
cell lines was used as positive controls, and mixtures with-
out sample DNA were used as negative controls. HPV ge-
notypes were determined using an HPV GenoArray Test
Kit (Hybribio, Chaozhou, China), according to the manu-
facturer’s instructions. Geno-Array is an L1 consensus
primer-based PCR assay [21] that is capable of amplifying
23 HPV genotypes, including 13 HR-HPV genotypes
(HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68),
3 PHR-HPV genotypes (HPV-53, 66, and 81) and 7 low-
risk HPV (LR-HPV) genotypes (HPV-6, 11, 42, 43, 44 and
61). The assay was conducted according to the manufac-
turer’s recommendations. PCR was performed in a reaction
volume of 25 μl containing 5 μl of DNA template, 19.25 μl
of the provided master mix, and 0.75 μl DNATaq polymer-
ase, using a Perkin-Elmer GeneAmp PCR System 9700
(Applied Biosystems) The amplification procedure was per-
formed as follows: 9 min of denaturation at 95 °C, followed
by 40 cycles of 20 s of denaturation at 95 °C, 30 s of
annealing at 55 °C, 30 s of elongation at 72 °C, and a final
extension for 5 min at 72 °C.
All the samples that were identified as positive
through PCR were genotype with two methods. First we
run Geno-Array test and secondly we performed direct
sequencing. For the DNA sequencing, new PCR was run
with reaction mixture 50 μL containing 6 μL of the
DNA extract, 1 μL of 10 μmolar MY09 primer, 1 μL of
10 μmolar MY11 primer and 25 μL of the provided mas-
ter mixture, and 15 μL dH2O. The consensus primer
products were separated by electrophoresis on a 2 %
agarose gel and purified with Tiangel PCR purification
kit. The DNA was then directly sequenced using the
ABI PRISM Big Dye Terminator Cycle Sequencing
Ready Reaction (Invitrogen, Beijing, CN) on an ABI 310
DNA analyzer. The nucleotide sequences were aligned
and compared with those of known HPV genotypes
available through Genbank by using the BLAST 2.0 soft-
ware server (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The
sample was identified as a particular HPV genotype if
the sequence was 95 % homologous with the reference
standard.
Statistical analysis
The Chi-square test was performed to compare the
differences in HPV genotype distribution among the
histo-pathologically normal and abnormal samples
and among the various regions. Data analysis was per-
formed using SPSS 20.0 (SPSS, Chicago, USA). All




All of the participants were recruited from various
regions of Yunnan province, China (Table 1 and
Fig. 1 show the regions inhabited by the study par-
ticipants). The median age of the 17,898 women in-
cluded in this study was 38 years, with a range of 18
to 93 years (mean = 40.5 years, SD = 8.79 years, 95 %
CI, 40.37–40.63). A total of 75.2 % women were
Han, and 24.8 % were of other ethnicities. In
addition, 38.3 % of the women came from rural
areas, and 61.7 % were from urban areas. Most of
the women (82.3 %) were married and reported hav-
ing a single sexual partner, and the mean number of
years of sexual activity was 17. Only 57.7 % of the
women had delivered a single baby. A summary of
the participants’ characteristics is shown in Table 1.
Of the 17,898 women, 16,968 (94.8 %) had normal,
458 had CIN1, 247 had CIN2, 181 had CIN3, and 44
had CC (Table 3).
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Table 1 The characteristics of HPV infected individuals
Overall Central North-west North-east South-west South-east
(n = 17898) (n = 7065) (n = 3772) (n = 3152) (n = 2164) (n = 1745)
Normal 16968 (94.8) 6704 (94.9) 3570 (94.6) 2984 (94.7) 2062 (95.3) 1648 (94.4)
CINI 458 (2.5) 173 (2.4) 97 (2.8) 85 (2.7) 51 (2.3) 52 (3.0)
CINII 247 (1.4) 103 (1.4) 56 (1.5) 40 (1.3) 23 (1.1) 25 (1.4)
CINIII 181 (1.0) 64 (0.9) 37 (1.0) 36 (1.1) 25 (1.5) 19 (1.1)
CC 44 (0.2) 21 (0.3) 12 (0.3) 7 (0.2) 3 (0.1) 1 (0.05)
Ethnic
Han 13465 (75.2) 5499 (77.8) 2841 (75.3) 2157 (68.4) 1658 (76.6) 1310 (75.1)
Others 4433 (24.8) 1566 (22.2) 931 (24.7) 995 (31.6) 506 (23.4) 435 (24.9)
Area
Rural 6849 (38.3) 2695 (38.1) 1462 (38.8) 1176 (37.3) 820 (37.9) 696 (39.9)
Urban 11049 (61.7) 4370 (61.9) 2310 (61.2) 1976 (62.7) 1344 (62.1) 1049 (60.1)
Education
Graduate 4399 (24.6) 1780 (25.2) 897 (23.8) 847 (26.9) 422 (19.5) 453 (25.9)
High 3841 (21.5) 1533 (21.7) 845 (22.4) 684 (21.7) 408 (18.8) 371 (21.3)
Middle 5564 (31.1) 2282 (32.3) 1114 (29.5) 892 (28.3) 733 (33.9) 543 (31.1)
Primary 2370 (13.2) 807 (11.4) 515 (13.6) 368 (11.3) 481 (22.2) 199 (11.4)
Illiterate 1724 (9.6) 663 (9.4) 401 (10.6) 361 (11.4) 120 (5.5) 179 (10.2)
Profession
Farmer 3886 (21.7) 1321 (18.7) 730 (19.3) 643 (20.4) 663 (30.7) 529 (30.3)
Government 3489 (19.5) 1407 (19.9) 663 (17.6) 602 (19.1) 496 (22.9) 321 (18.4)
Others 2410 (13.5) 968 (13.7) 547 (14.5) 351 (11.1) 307 (14.2) 237 (13.4)
Private 3918 (21.9) 1613 (22.8) 882 (23.4) 704 (22.3) 381 (17.6) 338 (19.4)
Services 2689 (15.9) 1141 (16.1) 619 (16.4) 497 (15.8) 253 (11.7) 179 (10.2)
No work 1506 (8.4) 615 (7.8) 331 (8.8) 355 (11.3) 64 (2.9) 141 (8.1)
Smoke
Yes 7619 (42.6) 2981 (42.2) 1565 (41.5) 1409 (44.7) 903 (41.7) 761 (43.6)
No 10279 (57.4) 4084 (57.8) 2207 (58.5) 1743 (55.3) 1261 (58.3) 984 (56.4)
Drinking
Yes 11203 (62.6) 4759 (67.4) 1613 (42.8) 2183 (69.2) 1469 (67.9) 1179 (67.6)
No 6695 (37.4) 2306 (32.6) 2159 (57.2) 969 (30.7) 695 (32.1) 566 (32.4)
Material status
Married 14675 (82.0) 5921 (83.3) 3078 (81.6) 2478 (78.6) 1799 (83.1) 1399 (80.2)
Single 3223 (18.0) 1144 (16.2) 694 (18.4) 674 (21.3) 365 (16.9) 346 (19.8)
Pregnancy
Single 10334 (57.7) 4511 (63.8) 2033 (53.9) 1653 (52.4) 1187 (54.8) 950 (54.4)
Multiple 7564 (42.3) 2554 (36.2) 1739 (46.1) 1499 (47.5) 977 (45.1) 795 (45.4)
Age groups
<35 years 6582 (36.8) 2779 (39.3) 1452 (38.5) 1092 (34.6) 759 (35.1) 500 (28.6)
36–45 6941 (38.9) 3195 (45.3) 957 (25.4) 1115 (35.4) 710 (32.8) 964 (55.2)
>46 years 4375 (24.4) 1091 (15.4) 1363 (36.1) 945 (30.0) 695 (32.1) 281 (16.1)
n number
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HPV genotype distribution by region
The overall HPV infection rate (19.9 %) among the south-
western women was significantly higher than that among
the north-western (18.0 %), south-eastern (13.3 %), north-
eastern (11.1 %) and central women (12.9 %). The high-risk
(HR) (18.1 %) and single genotype (16.7 %) infection rates
among the South-western women were also significantly
higher than those of among the north-western (13.9 %,
11.3 %), south-eastern (11.6 %, 10.5 %), north-eastern
(9.6 %, 9.1 %) and central women (10.5 %, 10.0 %), respect-
ively. While, the infections with other HPV (4.1 %) and with
multiple HPV (4.2 %) genotypes were significantly more
common (P = 0.001) among women in north-western than
women in the south-western (1.3 %, 3.1 %), south-eastern
(1.7 %, 2.7 %), north-eastern (1.5 %, 2.0 %) and central
women (2.4 %, 2.9 %). The HPV genotype distribution data
by region is shown in Table 4. The prevalence of HPV-16
(5.9 %) and HPV-58 (3.5 %) were significantly (P = 0.001, P
= 0.001) more frequent in the southwest region compared
with those in the central, north-east, south-east, and north-
west regions. With the exception of the above-mentioned
genotypes, no significance differences in the distributions of
any of the other HPV genotypes were observed among the
five regions of Yunnan province (Table 2).
HPV genotypes and histo-pathological grades
The prevalence of overall, HR-HPV, and single geno-
types infection significantly increased as the infection
progressed in advanced lesions. While, the prevalence of
multiple genotypes infection and other genotypes were
decreased as the infection progressed in advanced
lesions but the difference was not significant. HPV-16,
58, 52, and 18 were significantly more frequent in
advance abnormal cervical lesion that those of other ge-
notypes (Fig. 2). The distribution of HPV genotypes ac-
cording to cervical histo-pathological stage is shown in
Table 2. A total of 23 HPV genotypes were detected in
the histo-pathologically abnormal samples with different
prevalence rates. The six most common HPV genotypes
detected in the CINI samples were HPV-16, 52, 58, 53,
39, and 81. In the CINII samples, HPV-52 was the most
prevalent, followed by HPV-16, 58, 33, 81, and 51. How-
ever, in the CINIII and CC samples, HPV-16 was more
prevalent, followed by HPV-58, 18, and 52. A total of 30
HPV genotypes were detected in the normal group, the
most common of which were HPV-52, followed by
HPV-16, 58, 53, 18, 51, 68 and 81 (Table 3).
In this study, three PHR-HPV genotypes (HPV-53, 66,
and 81) were also detected, and they were highly preva-
lent in the CIN1 and CIN2 samples. Only three CC sam-
ples were found to have a co-infection with the HPV-66
and HR-HPV genotypes. Interestingly, eight single and
multiple LR-HPV infections were detected in both the
normal and abnormal cytology groups. Some of the un-
classified HPV genotypes, such as HPV-67, 69, 70, 71, 82
and 83, were also found in the control group. Table 3
shows the genotype distributions among the abnormal
cytology and control groups.
Fig. 1 Overview of study population
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Table 2 HPV Prevalence and genotype distribution among various regions of Yunnan province
Variable Overall Central North-east North-west South-east South-west P-Value
(n = 17898) n = 7065 n = 3152 n = 3772 n = 1745 n = 2164
Overalla 14.0 (13.5–14.5 12.9 (12.1–13.7) 11.1 (10.0–12.2) 18.0 (16.8–19.2) 13.3 (11.7–14.9) 19.9 (18.2–21.6) 0.001
High riska 12.2 (–11.7–12.7) 10.5 (9.8–11.2) 9.6 (8.6–10.6) 13.9 (12.0–14.2) 11.6 (10.1–13.1) 18.1 (16.5–19.7) 0.001
Othersa 1.8 (1.6–2.0) 2.4 (2.04–2.7) 1.5 (1.1–1.9) 4.1 (3.5–4.7) 1.7 (1.1–2.3) 1.3 (0.8–1.8) 0.001
Single infectiona 11.0 (10.5–11.4) 10.0 (9.3–10.7) 9.1 (8.1–10.1) 11.3 (10.3–12.3) 10.5 (9.1–11.9) 16.7 ((15.1–18.3) 0.001
Multiple infectiona 3.0 (2.8–3.2) 2.9 (2.5–3.3) 2.0 (1.5–2.5) 4.2 (3.6–4.8) 2.7 (1.9–3.5) 3.1 (2.4–3.8) 0.001
Unidentifieda 1.1 (0.9–1.2) 0.7 (0.5–0.9) 0.8 (0.5–1.1) 2.2 (1.7–2.7) 0.9 (0.5–1.3) 0.9 (0.5–1.3) 0.009
HR-HPV
HPV-52a 3.1 (2.9–3.3) 3.4 (3.0–3.8) 2.4 (1.9–2.9) 3.3 (2.7–3.9) 3.0 (2.2–3.8) 3.1 (2.4–3.8) 0.15
HPV-16a 3.4 (3.1–3.7) 3.0 (2.8–3.2) 2.4 (1.9–2.9) 3.5 (2.9–4.1) 3.4 (2.5–4.2) 5.9 (4.9–6.9) 0.001
HPV-58a 2.1 (1.9–2.3) 1.9 (1.6–2.2) 1.4 (1.0–1.8) 2.3 (1.8–2.8) 1.5 (0.9–2.1) 3.5 (2.7–4.3) 0.001
HPV-18a 1.2 (1.0–1.3) 1.1 (0.9–1.3) 1.4 (1.0–1.8) 1.4 (1.0–1.8) 13 (0.7) 1.5 (1.0–2.0) 0.16
HPV-51 120 (0.7) 49 (0.7) 18 (0.6) 23 (0.6) - 30 (1.4) 0.2
HPV-39 118 (0.6) 45 (0.6) 13 (0.4) 34 (0.9) 17 (1.0) 9 (0.4) 0.69
HPV-33 124 (0.7) 44 (0.6) 20 (0.6) 52 (1.4) - 8 (0.4) 0.35
HPV-68 122 (0.7) 43 (0.6) 19 (0.6) 31 (0.8) 9 (0.5) 20 (0.9)
HPV-56 60 (0.3) 32 (0.4) 4 (0.1) 8 (0.2) 8 (0.4) 8 (0.4)
HPV-59 56 (0.3) 27 (0.4) 3 (0.1) 19 (0.5) 5 (0.3) 2 (0.09)
HPV-31 63 (0.3) 23 (0.3) 9 (0.3) 11 (0.3) 7 (0.4) 13 (0.6)
HPV-35 (12) 0.07 7 (0.01) 5 (0.1) - - -
HPV-45 12 (0.07) 3 (0.04) 5 (0.1) - 4 (0.2) -
PHR-HPV
HPV-53 176 (1.0) 75 (1.1) 33 (1.0) 32 (0.8) 25 (1.4) 11 (0.5)
HPV-81 108 (0.6) 42 (0.6) 12 (0.4) 23 (0.6) 13 (0.7) 18 (0.8)
HPV-66 15 (0.2) 9 (0.3) 16 (0.4) 10 (0.6) 18 (0.8)
LR-HPV
HPV-11 68 (0.4) 14 (0.2) - 7 (0.2) 6 (0.3) 5 (0.2)
HPV-6 16 (0.09) 9 (0.1) - 4 (0.1) 3 (0.2) -
HPV-61 30 (0.2) - 9 (0.3) 5 (0.1) 7 (0.4) 9 (0.4)
HPV-43 15 (0.08) 7 (0.1) - - - 8 (0.4)
HPV-55 7 (0.04) 6 (0.08) 1 (0.03) - - -
HPV-44 12 (0.07) 5 (0.07) - - - 7 (0.3)
HPV-42 9 (0.05) 4 (0.06) - - 3 (0.2) 2 (0.09)
HPV-40 4 (0.02) - 4 (0.1) - - -
HPV-67 1 (0.005) - 1 (0.03) - - -
HPV-69 1 (0.005) - 1 (0.03) - - -
HPV-70 2 (0.01) 2 (0.03) - - - -
HPV-71 3 (0.002) 3 (0.04) - - - -
HPV-82 6 (0.03) 1 (0.02) - - 2 (0.1) 3 (0.1)
HPV-83 2 (0.01) - - 1 (0.02) - 1 (0.05)
n number, a95% Confidence interval
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HPV genotypes and infection
The distribution of HPV genotypes according to the type
of infection is shown in Table 3. A total of 16,968 women
had normal cytological (normal group) results, and of
them, 8.3 % (1402/16968) were infected with a single HPV
genotype. In contrast we identified the presence of HPV
DNA in 60.4 % (562/930) of the women in the abnormal
histo-pathological group. Multiple genotype infections
were the most common, and the rate of this type of infec-
tion was significantly higher (Table 2, P = 0.001) in the ab-
normal histo-pathological group (236/930, 24.4 %)
compared with that in the normal group (1.8 %, 304/
16968). The proportion of uncharacterised infection was
also higher in the abnormal histo-pathological group
(7.1 %, 68/930) compared with that in the normal group
(0.75 %, 128/16968). The distribution of HPV genotypes
according to the type of infection is shown in Table 3. In
cases of single infection, HPV-16 (abnormal histo-
pathological group = 136/562, 24.2 %; normal group = 280/
16968, 1.6 %; P = 0.001), 18 (abnormal histo-pathological
group = 48/562, 8.5 %; normal group = 84/16968, 0.5 %; P
= 0.003), 33 (abnormal histo-pathological group = 36/562,
6.4 %; normal group = 48/16968, 0.3 %; P = 0.001), and 58
(abnormal histo-pathological group = 88/562, 15.7 %; nor-
mal group = 152/16968, 0.9 %; P = 0.001) were detected
significantly more frequently in the abnormal histo-
pathological group compared with the control group. In
addition, HPV-31 (abnormal histo-pathological group = 3/
562, 0.5 %; normal group = 36/16968, 0.21 %; P = 0.002), 51
(abnormal histo-pathological group = 8/562, 1.4 %; normal
group = 52/1402, 0.3 %; P = 0.001), 61 (abnormal histo-
pathological group = 3/562, 0.5 %; normal group = 24/
16968, 0.1 %; P = 0.05), 66 (abnormal histo-pathological
group = 3/562, 0.5 %; normal group = 24/16968, 0.1 %; P =
0.05), and 68 (abnormal histo-pathological group = 10/562,
1.8 %; normal group = 52/16968, 0.3 %; P = 0.001) were sig-
nificantly more common in the normal group compared
with the abnormal histo-pathological group (Table 4).
To determine the possible variation in HPV geno-
type distribution among the various age groups, the
abnormal histo-pathological and normal groups were
stratified into three groups according to age. Correl-
ation analysis revealed that HPV prevalence was more
complex in the younger and older participants com-
pared with the middle age group (Figs. 3 and 4). The
highest overall, HR-HPV and multiple HPV prevalence
was observed in the <35 years age group, and it de-
clined thereafter with increasing age. A less pro-
nounced second peak in prevalence was observed for
the normal women in the older age group (>46 years).
However, overall, high-risk and multiple-genotype in-
fections among the abnormal histo-pathological
women exhibited two peaks in prevalence, with the
first peaks of 88.9, 63.5 and 25.5 %, respectively, oc-
curring at <35 years and the second peaks of 95.5,
64.3 and 31.2 % occurring at >46 years. Overall, we
Fig. 2 Distribution of leading HPV genotypes among various histo-pathological lesions
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Table 3 Prevalence of Human Papillomavirus (HPV) and its genotype distribution among normal and histo-pathological abnormal
lesion
Variable Normal CIN1 CIN2 CIN3 SCC P-Value
(n = 16968) (n = 458) (n = 247) (n = 181) (n = 44)
overalla 10.0 (9.5–10.4) 81.2 (77.6–84.8) 86.2 (81.9–90.5) 94.5 (91.2–97.8) 95.4 0.001
High riska 9.1 (8.7–9.5) 64.0 (59.6–68.4) 65.2 (59.3–71.1) 80.1 (74.3–85.9) 88.6 (79.2–98.0) 0.001
Othersa 166 (1.0) 17.2 (13.8–20.6) 21.0 (15.9–26.1) 14.4 (9.3–19.5) 6.8 0.17
Singlea infectiona 8.3 (7.9–8.7) 56.8 (51.9–60.9) 55.5 (49.3–61.7) 72.4 (65.9–78.9) 77.3 (64.9–89.7) 0.001
Multiple infectiona 1.8 (1.6–2.0) 24.4 (20.5–28.3) 30.8 (25.1–36.5) 22.1 (16.1–28.1) 18.2 (6.8–29.6) 0.5
Unidentifieda 0.7 7.0 (4.7–9.3) 8.1 (4.7–11.5) 6.6 (3.0–10.2) 9.1 (0.6–17.6)
HR-HPV
HPV-16a 2.2 (1.9–2.4) 21.0 (17.3–24.7) 16.2 (11.6–20.8) 33.1 (26.3–39.9) 45.4 (30.7–60.1) 0.001
HPV-52a 2.3 (2.1–2.5) 20.1 (16.4–23.8) 19.4 (14.5–24.3) 11.0 (6.5–15.5) 15.9 (5.1–26.7) 0.025
HPV-58a 1.4 13.1 (10.0–16.2) 14.6 (10.2–20.0) 19.9 (14.1–25.7) 18.2 (6.8–29.6) 0.04
HPV-18a 0.6 5.2 (3.2–7.2) 1.6 (0.03–3.2) 17.7 (12.1–23.3) 18.2 (6.8–29.6) 0.001
HPV-51 92 (0.5) 16 (3.5) 12 (4.8) - -
HPV-68 84 (0.5) 23 (5.0) 8 (3.2) 7 (3.9) -
HPV-33 80 (0.5) 20 (4.4) 20 (8.1) 4 (2.2) -
HPV-39 76 (0.4) 28 (6.1) 8 (3.2) 4 (2.2) -
HPV-31 48 (0.3) 6 (1.3) 4 (1.6) 5 (2.8) -
HPV-56 40 (0.2) 8 (1.7) 8 (3.2) 4 (2.2) -
HPV-59 40 (0.2) 8 (1.7) - 4 (2.2) 4 (9.1)
HPV-45 4 (0.02) 6 (1.3) - 2 (1.1) -
HPV-35 9 (0.05) 3 (0.6) - - -
PHR-HPV
HPV-53 128 (0.7) 28 (6.1) 20 (8.1) - -
HPV-81 52 (0.3) 24 (5.2) 19 (7.7) 12 (6.6) -
HPV-66 44 (0.2) 8 (1.7) 8 (3.2) 4 (2.2) 3 (6.8)
Others
HPV-61 24 (0.1) - 3 (1.2) - -
HPV-11 24 (0.1) - 4 (1.6) 4 (2.2) -
HPV-6 12 (0.07) - - 4 (2.2) -
HPV-43 8 (0.05) 4 (0.9) - 3 (1.6) -
HPV-44 8 (0.05) 4 (0.9) - - -
HPV-42 4 (0.02) 2 (0.4) - 3 (1.6) -
HPV-55 4 (0.02) 3 (0.6) - - -
HPV-40 4 (0.02) - - - -
HPV-67 1 (0.005) - - - -
HPV-69 1 (0.005) - - - -
HPV-70 2 (0.01) - - - -
HPV-71 3 (0.01) - - - -
HPV-82 6 (0.03) - - - -
HPV-83 2 (0.01) - - - -
n number, a95 % Confidence interval
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did not find significant differences among the various
age groups in HPV genotype distribution. Correlation
analysis revealed that the HPV genotype prevalence’s
were highly correlated in single and multiple infec-
tions among the younger women (<35 years) and older
women in both the normal and abnormal histo-
pathological groups. However, HPV-16 was more frequent
in the younger women (<35 years) in both the normal and
abnormal histo-pathological groups. The prevalence’s of
other genotypes, such as HPV-52, 58, 68, 33, 53, and 66,
were found vary among the different age groups and vary-
ing histo-pathological grades (Table 5).
Table 4 Prevalence of Human Papillomavirus (HPV) and its genotypes among normal and histo-pathological abnormal cases with
Single or Multiple genotypes infection
Single infection Multiple infection
Variable Normal Abnormal P-value Control Abnormal P-value
(n = 16968) (n = 930) (n = 16968) (n = 930)
Overalla 8.3 (7.9–8.7) 60.4 (58.8–62.0) 0.001 1.8 (1.6–2.0) 25.4 (22.6–28.2) 0.001
Unidentifieda 0.7 (0.6–0.8) 7.3 (5.6–9.0) 0.001 - -
HPV-16a 1.6 (1.4–1.8) 14.6 (12.3–16.9) 0.001 0.6 (0.5–0.7) 9.9 (8.0–11.8) 0.001
HPV-52a 1.6 (1.4–1.8) 10.3 (8.4–12.2) 0.001 0.6 (0.5–0.7) 7.7 (6.0–9.4) 0.001
HPV-58a 0.9 (0.8–1.0) 9.5 (7.6–11.4) 0.001 0.5 (0.4–0.6) 5.6 (4.1–7.1) 0.001
HPV-18 84 (0.5) 48 (5.2) 0.001 52 (0.3) 36 (3.9) 0.001
HPV-68 52 (0.3) 10 (1.1) 0.002 32 (0.2) 28 (3.0) 0.001
HPV-51 52 (0.3) 8 (0.9) 0.012 40 (0.2) 20 (2.1) 0.001
HPV-33 48 (0.3) 36 (3.9) 0.001 32 (0.2) 8 (0.9) 0.01
HPV-39 48 (0.3) 12 (1.3) 0.001 28 (0.2) 28 (3.0) 0.001
HPV-31 36 (0.2) 3 (0.3) 0.45 12 (0.07) 12 (1.3) 0.001
HPV-59 28 (0.2) 12 (1.3) 0.001 12 (0.07) 4 (0.4) 0.008
HPV-56 20 (0.1) - 20 (0.1) 16 (1.7) 0.001
HPV-45 4 (0.02) - - 8 (0.9)
HPV-35 3 (0.02) - 6 (0.03) 3 (0.3) 0.008
PHR-HPV
HPV-53 88 (0.5) 24 (2.6) 0.001 40 (0.2) 24 (2.6) 0.001
HPV-66 24 (0.1) 3 (0.3) 0.16 20 (0.1) 20 (2.1) 0.001
HPV-81 20 (0.1) 11 (1.2) 0.001 32 (0.2) 44 (4.7) 0.001
LR-HPV
HPV-61 24 (0.1) 3 (0.3) 0.16 - -
HPV-11 - - 24 (0.1) 8 (0.9) 0.001
HPV-6 - - 12 (0.07) 4 (0.4) 0.008
HPV-42 - - 5 (0.03) 4 (0.4) 0.001
HPV-55 4 (0.02) 3 (0.3) - -
HPV-40 4 (0.02) - -
HPV-44 4 (0.02) - 4 (0.02) 4 (0.4) 0.001
HPV-43 3 (0.01) - 4 (0.02) 8 (0.9) 0.001
Unclassified
HPV-82 7 (0.04) - - -
HPV-71 3 (0.02) - - -
HPV-70 2 (0.01) - - -
HPV-83 2 (0.01) - - -
HPV-67 1 (0.005) - - -
HPV-69 1 (0.005) - - -
n number, a95 % Confidence interval
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Fig. 3 Age-specific HPV prevalence among normal cases
Fig. 4 Age-specific HPV prevalence among histo-pathological abnormal cases
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Discussion
Many studies have reported the HPV prevalence and its
genotype distributions in various provinces of P. R. China
[22, 23]. However, no relevant epidemiological data are
available for Yunnan province. To the best of our
knowledge, the current study is the first to report the epi-
demiological prevalence and distribution of HPV genotypes
in various region of Yunnan. Samples screened in this
study were obtained from different ethnic populations
from different geographic regions of Yunnan province.
Table 5 Prevalence of Human Papillomavirus (HPV) genotypes in according to histo-pathological result among various Age groups







P-value >35 years (n = 326) 36–45 years (n = 318) <46 years (n = 286) P-Value
Overall 721 (12.1) 592 (9.1) 443 (9.9) 0.001 290 (88.9) 235 (73.9) 273 (95.4) 0.045
Single 579 (9.7) 502 (7.7) 321 (7.2) 0.001 207 (63.5) 171 (53.8) 184 (64.3) 0.9
Multiple 142 (2.4) 90 (1.4) 122 (2.7) 0.44 83 (25.5) 64 (20.1) 89 (31.2) 0.13
HR-HPV 1087
HPV-16 160 (2.7) 132 (2.0) 88 (2.0) 0.018 100 (30.7) 80 (25.1) 48 (16.8) 0.001
HPV-52 153 (2.5) 119 (1.8) 120 (2.7) 0.003 63 (19.3) 61 (19.2) 16 (5.6) 0.001
HPV-58 98 (1.6) 69 (1.0) 65 (1.4) 0.016 52 (15.5) 80 (25.1) 36 (12.6) 0.37
HPV-18 64 (1.1) 41 (0.6) 31 (0.7) 0.022 22 (6.7) 37 (11.6) 25 (8.7) 0.35
HPV-68 40 (0.7) 31 (0.5) 13 (0.3) 0.024 10 (3.1) 25 (7.9) 3 (1.0) 0.27
HPV-33 44 (0.7) 24 (0.4) 12 (0.3) 0.001 20 (6.1) 24 (7.5) -
HPV-51 29 (0.5) 43 (0.6) 20 (0.4) 0.25 12 (3.7) 16 (5.0) -
HPV-56 12 (0.2) 16 (0.2) 10 (0.2) 0.87 8 (2.4) - 8 (2.8)
HPV-31 10 (0.2) 15 (0.2) 23 (0.5) 0.002 8 (2.4) 6 (1.9) 1 (0.3)
HPV-59 10 (0.2) 21 (0.3) 9 (0.2) 5 (1.5) 3 (0.9) 8 (2.8)
HPV-39 8 (0.1) 32 (0.5) 16 (0.3) 8 (2.4) 18 (5.7) 14 (4.9)
HPV-35 4 (0.07) 2 (0.03) 3 (0.07) - 3 (0.9) -
HPV-45 1 (0.02) 3 (0.04) - 2 (0.6) - 6 (2.1)
PHR-HPV 132
HPV-53 28 (0.5) 56 (0.8) 44 (1.0) 0.003 16 (4.9) 16 (5.0) 16 (5.6) 0.7
HPV-66 23 (0.4) 11 (0.2) 10 (0.2) 0.05 13 (4.0) 6 (1.9) 4 (1.4)
HPV-81 20 (0.3) 12 (0.2) 20 (0.4) 0.042 - 22 (6.9) 15 (5.2)
Others 183 - - -
HPV-83 - 2 (0.03) - - - -
HPV-69 - 1 (0.01) - - - -
HPV-70 - 2 (0.03) - - - -
HPV-71 - - 3 (0.07) - - -
HPV-82 4 (0.05) - 3 (0.07) - - -
HPV-67 1 (0.02) - - - - -
HPV-61 11 (0.2) 7 (0.1) 6 (0.1) 0.5 3 (0.9) - -
HPV-11 10 (0.2) 7 (0.1) 7 (0.1) 0.63 - - 8 (2.8)
HPV-6 5 (0.08) 7 (0.1) - - - 4 (1.4)
HPV-40 4 (0.07) - -
HPV-44 4 (0.07) 4 (0.06) - - 4 (1.2) -
HPV-43 2 (0.03) - 5 (0.1) - 3 (0.9) 5 (1.7)
HPV-42 1 (0.02) 3 (0.04) 1 (0.02) - 4 (1.2) -
HPV-55 - 4 (0.06) - - 3 (0.9) -
Unidentified 44 (0.7) 76 (1.2) 8 (0.2) 0.001 28 (8.6) 32 (10.1) 8 (2.8) 0.008
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Therefore, the results of this study provide precise estima-
tions of the HPV prevalence and genotype distributions in
histo-pathological abnormal and normal cervical samples
obtained from women throughout Yunnan province.
In this study, the overall HPV infection rate of 14.0 %
was higher than the documented rates in neighbouring
countries (6.2 % in Southeast Asia, 6.6 % in south central
Asia and 8.0 % in other Asian countries [15, 24]. How-
ever, reports from some regions of mainland China have
stated that the overall prevalence is 18.4 % in Shenzhen
city [25], 13.3 % in Zhejiang province [26] and 14.8 % in
Shanxi province [27], in agreement with our reported
HPV prevalence. HPV prevalence has been documented
to vary in different geographic regions, e.g., it is 8.1 % in
Europe, 11.3 % in North America, 22.1 % in Africa and
8.0 % in Asia [15]. Here, we found that its prevalence
was significantly higher among the south-western
women (19.9 %) than the women from other four re-
gions. The HPV prevalence in the south-western and
north-western region was in line with the previously
reported infection rate for north-western region of Yun-
nan (18.4 %) [27, 28]. However, the HR-HPV prevalence
in the south-western women was very high compared
with Zhejiang (10.2 %) and Shanxi (12.2 %) [29, 30]. The
LR-HPV prevalence rates have been reported to be 3.8
and 4.4 % in Shanxi and Taiwan, respectively [29], which
is in accordance with our identified LR-HPV prevalence
of 4.1 % among the north-western region women.
Comparatively, the calculated LR-HPV prevalence rate
among the central, south-western, south-eastern and
north-eastern regions women is similar to those in areas
with lower LR-HPV prevalence rates in China, such as
Shandong and Tibet [29, 31].
The distribution of HPV genotypes varies significantly
in different geographic locations worldwide [15]. HPV-
16 is the most frequently detected genotype in all
regions of the world, followed by HPV-58 and 52 in Asia
[24], HPV-58 in South America and HPV-31 in Europe
[5]. In China, HPV-16 is the most prevalent genotype,
followed by HPV-52 and 58 [26]. Moreover, HPV-33 and
31 are highly prevalent in some regions [27]. Such vari-
ation was also observed in this study, with HPV-52 being
the most prevalent genotype in the central and north-
east regions, followed by HPV-16 and 58. Interestingly
HPV-18 is the 3rd most prevalent genotype in the
north-east region only. In the north-west and south-east
regions, HPV-16 is the most frequent, followed by HPV-
52 and 58. Further, HPV-16 is most common in the
south-west region, followed by HPV-58 and 52 (Table 5).
Our study findings do not support previously reported
data that infection with multiple genotypes increases the
risk of cervical cancer. Infection with multiple genotypes
was significantly more frequent in the CINI and CIN2 sam-
ples. However, the prevalence this type of infection abruptly
decreased with progression to CIN3 or cervical cancer. Fur-
ther, infections with a single HR-HPV genotype resulted in
an increase in cervical lesion progression. This finding
might indicate that there is a lower risk of developing ma-
lignancy with multiple genotype infections compared with
single genotype infections [32, 33] (Table 1).
Analysis of the specific HPV genotype distribution in
the abnormal histo-pathological group indicated that it
was highly variable in the histo-pathological abnormal
lesions. HPV-16 (45.4 %) was the most frequently de-
tected genotype in SCC, followed by HPV-58 (18.2 %),
18 (18.2 %), and 52 (15.9 %). Interestingly, 8 SCC
patients were also found to have a multiple genotype in-
fection (co-infection of HPV-59 and 66 with HPV-52
and 58, and 18). These findings are in complete agree-
ment with previously reported data, indicating that
HPV-16, 18, 52, and 58 are most frequently present in
cervical cancer [9, 34]. HPV-16, 58, 18 and 52 were also
frequent in the CIN3 samples, which is consistent with
previous reports [25, 35]. All of these genotypes are con-
sidered to be highly oncogenic and are the most fre-
quently detected HPV genotypes worldwide. Previous
studies conducted in China and some other parts of the
world have indicated that HPV-52 is the most frequent
genotype in Asia, and particularly in China [25, 30]. In
this study, HPV-52 was also a predominant genotype;
however, its prevalence was higher in CIN1 and CIN2
samples compared with that in advanced cervical lesions.
Based on these observations, infection with HPV-16, 58,
and 18 might be associated with an elevated risk of cer-
vical cancer development in the infected population.
However, the declining trend in HPV-52 prevalence in
advanced cervical lesions might be due to host immune
factors or geographic or environmental factors [36]. In
this study, we found high prevalence of other HR-HPV
genotypes, such as HPV-33, 31, 39, 51, and 68, in the ab-
normal histo-pathological group. These genotypes were
more common in the CIN1, CIN2 and CIN3 lesions
than in SCC. HPV-31 and 33 are highly carcinogenic ge-
notypes that are present worldwide [33, 37]. However, in
this study, we did not find them to be highly carcino-
genic, which may be due to variable geographic factors,
biological factors, lifestyle, or human and viral genetic
factors. Further, we found a high prevalence of PHR-
HPV, particularly HPV-53 and 81 and the LR-HPV geno-
types HPV-6 and 11. However, these genotypes were
only identified in multiple genotype infections. These
findings are in line with previously reported data [38]. In
this study, the prevalence of HR-HPV was increased in
samples with advanced histo-pathological grades. The
incidence of HR-HPV infection, and particularly that of
single genotype infection, was very high in the abnormal
histo-pathological group compared with that in the nor-
mal group. These findings are in accordance with those
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of Castle et al. [39]. On the basis of these observations,
we suggest that attention should be paid to the histo-
pathological outcomes of CIN2, CIN3 and higher-grade
lesions, even in the absence of specific genotype
information.
In this study, we also evaluated the HPV genotype dis-
tributions among different age groups. HPV-16 was
more frequent in women less than 35 years old in both
the normal and abnormal cytology groups. However, the
distributions of the other genotypes varied among the
different age groups with lesions of differing cytology
grades. HPV-52 and 18 showed double-peak prevalence
in the normal cytology group. The prevalence of HPV-
52 in the abnormal cytology group decreased with
increasing age; however, that of HPV-18 increased with
increasing age in this group. Such variation has also
been observed for other genotypes, as shown in Table 4.
These findings indicate that various age groups possess
different genotypes in lesions with differing cytological
grades [40]. Thus, it is very important to determine the
potential roles of the different HPV genotypes in car-
cinogenesis development among various age groups and
to further determine their potential risk and contribu-
tion to carcinogenesis in future studies.
The results of this study suggest that cervical screen-
ing is vital for women, particularly minority ethnic
women, to prevent HPV-related cervical cancer [41]. An
important link between HPV infection and development
of cervical neoplasia has been identified in this study.
Thus, the timely detection of HPV infection would be
very helpful for preventing disease progression, consider-
ing that its early detection in patients with cervical le-
sions has been well established to result in a decrease in
the rate of cancer development [42].
There are some limitations of this study that must be
considered when interpreting our findings. Yunnan in-
cludes 26 state-certified ethnic minorities who live in
different regions of the province. Most of them do not
want to participate in epidemiological studies due to
their ethnic beliefs. In this study, we focused only on
those women who visited a public hospital with routine
gynaecological examination.
Conclusion
This study provides epidemiological estimates of HPV
genotype distributions in different regions of the prov-
ince and further reports the prevalence of these geno-
types in neoplastic lesions with differing cytological
grades. We have found that overall, HPV-16, 52, 58, and
18 are the most common HR-HPV genotypes. However,
the prevalence rates of these genotypes significantly dif-
fer in different regions of the province. PHR-HPV-53 is
also a predominant genotype in some regions. These
variations could be due to the large number of ethnic
populations residing in the province. A vaccine currently
under trial has been formulated for HPV-16, 18, 11, and
6, and it will be introduced nationally in the coming
years. However, HPV-52 and 58 are the predominant ge-
notypes in several regions. Thus, based on our observa-
tions, a new tetravalent vaccine may be more effective
than a bivalent vaccine in China, and particularly in
Yunnan province. Further, due to large-scale geographic
variation in HPV genotype distribution, a future large-
scale, multi-ethnic population-based study must be con-
ducted to obtain comprehensive information on the
prevalence and genotype distribution of HPV in various
Chinese ethnic populations.
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